5:56 PM
Nov 27, 2012
 |  BC Extra  |  Clinical News

Acadia jumps on Phase III pimavanserin data

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $3.13 (136%) to $5.43 on Tuesday after reporting that once-daily 40 mg oral pimavanserin as an adjunct to stable doses of existing anti-Parkinson's therapy met the primary endpoint in the Phase III ACP-103-020 trial to treat Parkinson's disease psychosis (PDP). Specifically, primavanserin improved antipsychotic efficacy as measured by the mean reduction from baseline to day 43 in scores on the SAPS-PD 9-item scale...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >